Bridging Glycemic and Lipid Control: Effects of Dapagliflozin in Co-Morbid Diabetes and Heart Failure – A Randomized Controlled Trial

Authors

Institutions

Publication Details

Journal
Endocrine Metabolic & Immune Disorders - Drug Targets
Published
2026-01-15
DOI
https://doi.org/10.2174/0118715303398749251027044323
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Bridging Glycemic and Lipid Control: Effects of Dapagliflozin in Co-Morbid Diabetes and Heart Failure – A Randomized Controlled Trial

Sarumathy Sundararajan, Laxmi Sankalpa Bhaganagarapu, Vengatesh Munusamy
Endocrine Metabolic & Immune Disorders - Drug Targets
Diabetes Treatment and Management
article

Bridging Glycemic and Lipid Control: Effects of Dapagliflozin in Co-Morbid Diabetes and Heart Failure – A Randomized Controlled Trial

Sarumathy Sundararajan, Laxmi Sankalpa Bhaganagarapu, Vengatesh Munusamy
article en

Abstract

No abstract available for this paper.
Endocrine Metabolic & Immune Disorders - Drug TargetsVol. 26
SRM Institute of Science and Technology (IN)
Good health and well-being
Openalex Percentile: Top 79%
Diabetes Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Bridging Glycemic and Lipid Control: Effects of Dapagliflozin in Co-Morbid Diabetes and Heart Failure – A Randomized Controlled Trial — Sarumathy Sundararajan, Laxmi Sankalpa Bhaganagarapu, et al. · Endocrine Metabolic & Immune Disorders - Drug Targets (2026) | TGRS Research Map | TGRS